JP2022507214A5 - - Google Patents

Info

Publication number
JP2022507214A5
JP2022507214A5 JP2021525675A JP2021525675A JP2022507214A5 JP 2022507214 A5 JP2022507214 A5 JP 2022507214A5 JP 2021525675 A JP2021525675 A JP 2021525675A JP 2021525675 A JP2021525675 A JP 2021525675A JP 2022507214 A5 JP2022507214 A5 JP 2022507214A5
Authority
JP
Japan
Prior art keywords
metal
ion
metal complex
complex according
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021525675A
Other languages
English (en)
Japanese (ja)
Other versions
JP7744240B2 (ja
JP2022507214A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/081014 external-priority patent/WO2020099398A1/en
Publication of JP2022507214A publication Critical patent/JP2022507214A/ja
Publication of JP2022507214A5 publication Critical patent/JP2022507214A5/ja
Priority to JP2023137271A priority Critical patent/JP2023179429A/ja
Application granted granted Critical
Publication of JP7744240B2 publication Critical patent/JP7744240B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021525675A 2018-11-12 2019-11-12 キレート化aaztaコンジュゲートおよびその錯体 Active JP7744240B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023137271A JP2023179429A (ja) 2018-11-12 2023-08-25 キレート化aaztaコンジュゲートおよびその錯体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18205796 2018-11-12
EP18205796.8 2018-11-12
PCT/EP2019/081014 WO2020099398A1 (en) 2018-11-12 2019-11-12 Chelating aazta conjugates and complexes thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023137271A Division JP2023179429A (ja) 2018-11-12 2023-08-25 キレート化aaztaコンジュゲートおよびその錯体

Publications (3)

Publication Number Publication Date
JP2022507214A JP2022507214A (ja) 2022-01-18
JP2022507214A5 true JP2022507214A5 (cg-RX-API-DMAC7.html) 2022-11-18
JP7744240B2 JP7744240B2 (ja) 2025-09-25

Family

ID=64308553

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021525675A Active JP7744240B2 (ja) 2018-11-12 2019-11-12 キレート化aaztaコンジュゲートおよびその錯体
JP2023137271A Pending JP2023179429A (ja) 2018-11-12 2023-08-25 キレート化aaztaコンジュゲートおよびその錯体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023137271A Pending JP2023179429A (ja) 2018-11-12 2023-08-25 キレート化aaztaコンジュゲートおよびその錯体

Country Status (5)

Country Link
US (1) US11684682B2 (cg-RX-API-DMAC7.html)
EP (1) EP3880635B1 (cg-RX-API-DMAC7.html)
JP (2) JP7744240B2 (cg-RX-API-DMAC7.html)
CN (1) CN112996764B (cg-RX-API-DMAC7.html)
WO (1) WO2020099398A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3880635B1 (en) * 2018-11-12 2023-01-04 Bracco Imaging SPA Chelating aazta conjugate, complexes thereof and use
DE102021111452B3 (de) * 2021-05-04 2022-07-28 Positron Precision GmbH Markierungsvorläufer und Radiotracer für neuroendokrine Theranostik
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
IL317339A (en) 2022-07-28 2025-01-01 Bracco Imaging Spa 1,4-Bis-(2-hydroxybenzyl)-1,4,7-triazaciconanone derivatives and similar compounds as ligands in iron(III) complexes for use as MRI contrast agents
CN122228249A (zh) 2023-12-06 2026-06-16 伯拉考成像股份公司 用于与铁离子过量和/或蓄积相关的疾病的化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7893223B2 (en) 2001-07-17 2011-02-22 Bracco Imaging S.P.A. Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy
ITMI20011518A1 (it) 2001-07-17 2003-01-17 Bracco Imaging Spa Leganti azotati multidentati capaci di complessare ioni metallici e loro uso in diagnostica e in terapia
EP1765812B1 (en) 2004-07-02 2009-04-29 Bracco Imaging S.p.A Contrast agents endowed with high relaxivity for use in magnetic resonance imaging (mri) which contain a chelating moiety with polyhydroxylated substituents
EP2111237B1 (en) 2006-12-11 2015-03-18 BRACCO IMAGING S.p.A. Fibrin-binding peptides and conjugates thereof
EP1964846A1 (en) * 2007-02-27 2008-09-03 Bracco Imaging, S.P.A. Process for the preparation of contrast agents
FR2914304B1 (fr) * 2007-03-28 2012-11-16 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de vcam.
EP2639227A1 (en) 2012-03-14 2013-09-18 Bracco Imaging S.p.A A new class of diazepine derivative chelating agents and complexes with paramagnetic metals as MRI contrast agents
US10351539B2 (en) * 2014-07-28 2019-07-16 INSERM (Institut National de la Santé et de le Recherche Médicale) Macrocyclic complexes, their process of preparation and use as PET imaging agents
DE102014115154A1 (de) * 2014-10-17 2016-04-21 SCV-SpezialChemikalien-Vertrieb GmbH Konjugierte Bisphosphonate für die Diagnostik und Therapie von Knochenerkrankungen
CN108473538B (zh) * 2015-10-28 2022-01-28 塔弗达治疗有限公司 Sstr靶向缀合物及其颗粒和制剂
EP3880635B1 (en) * 2018-11-12 2023-01-04 Bracco Imaging SPA Chelating aazta conjugate, complexes thereof and use
CN213135750U (zh) * 2020-08-28 2021-05-07 苏州信毅捷自动化科技有限公司 一种便于拆卸的曲柄压装设备

Similar Documents

Publication Publication Date Title
US11707539B2 (en) FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto
ES2593127T5 (es) Proceso para preparar una formulación farmacéutica de agentes de contraste
US10500292B2 (en) PSMA-binding agents and uses thereof
JP2017121233A5 (cg-RX-API-DMAC7.html)
WO2018213808A1 (en) Cd206+ macrophage-specific molecular imaging probe compositions and methods and the noninvasive quantification of arterial wall macrophage infiltration in humans
JP2010512369A5 (cg-RX-API-DMAC7.html)
JP2010523599A5 (cg-RX-API-DMAC7.html)
Rossetti et al. Human biodistribution, dosimetry and clinical use of technetium (III)-99m-Q12
EP3383385B2 (en) Melflufen dosage regimens for cancer
JP2021521209A (ja) 鉄過剰症の治療のための組成物及び方法
US20080138440A1 (en) Methods of diagnosing and alleviating gadolinium toxicity
JP2021502358A5 (cg-RX-API-DMAC7.html)
JP2023062146A (ja) アスタチン溶液及びその製造方法
JP2018502150A5 (cg-RX-API-DMAC7.html)
JP2021185141A (ja) サルコイドーシスを処置するための1,3−プロパンジスルホン酸またはその薬学的に許容される塩の使用
JP2015514689A5 (cg-RX-API-DMAC7.html)
CN117677405A (zh) 具有较高吸收率的靶向系统
JP7802851B2 (ja) 放射性標識されたgprpアンタゴニスト及び界面活性剤を含む医薬組成物
US20240207292A1 (en) Boronic acid compounds, compositions and methods
WO2009108868A2 (en) Radiolabeled hedgehog derivatives for imaging and therapy
Minutoli et al. Combined use of peptide receptor radionuclide therapy and metronomic chemotherapy in neuroendocrine tumors: a possible choice driven by nuclear medicine molecular imaging
KR20260057408A (ko) 신경내분비암의 진단 및/또는 치료 방법
JP2025535957A (ja) がんの特定および/または治療
US20250387523A1 (en) Combination therapy of radionuclide complex
IL325208A (en) Radiolabeled compound for use in a method of treating carbonic anhydrase positive diseases ix